Piper discusses potential takeout candidates after Amylin

Piper Jaffray highlights BioMarin (BMRN), Affymax (AFFY), Theravance (THRX), and Rigel Pharmaceuticals (RIGL) as potential takeout candidates in the biotech space following Bristol-Myers' (BMY) acquisition of Amylin (AMLN). Piper believes an acquisition of BioMarin could be valued at $79 per share, and says Takeda could be the most likely suitor for Affymax.